For #Biotechnology Winners:
Akero Therapeutics $AKRO +27% after reporting 16-week data from Phase 2a study of efruxifermin. 
AxoGen $AXGN +25% after reporting quarterly results. 
$SPX $QQQ #IBB #XBI Update https://t.co/krpZhK5XS9 https://t.co/j90694tNB4